Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Antineoplastic Agents. Found 204 abstracts

no pagination
Goldsack JC, Reilly C, Bush C, McElligott S, Bristol MN, Motanya UN, Field R, Vozniak JM, Wong YN, Schwartz JS, Domchek S. Impact of shortages of injectable oncology drugs on patient care. Am J Health Syst Pharm. 2014 Apr;71(7):571-8.
Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J, Viner J, McDevitt J, LoRusso P. Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors. Clin Cancer Res. 2014 Sep 15;20(18):4747-57.   PMCID: 4377301
Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, Cohen RB. Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol. 2014 Oct;32(28):3103-10.
Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA, Romeo C, Jimbo M, Norris ZA, Yeo CJ, Sawicki JA, Winter JM, Rigoutsos I, Yen TJ, Brody JR. HuR Posttranscriptionally Regulates WEE1: Implications for the DNA Damage Response in Pancreatic Cancer Cells. Cancer Res. 2014 Feb 15;74(4):1128-40.   PMCID: 4353573
Murray JC, Aldeghaither D, Wang S, Nasto RE, Jablonski SA, Tang Y, Weiner LM. c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity. Cancer Immunol Res. 2014 Dec;2(12):1186-98.   PMCID: 4258447
Plimack ER, Tan T, Wong YN, von Mehren MM, Malizzia L, Roethke SK, Litwin S, Li T, Hudes GR, Haas NB. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma. The oncologist. 2014 Apr;19(4):354-5.   PMCID: Pmc3983829
Shen C, Chien CR, Geynisman DM, Smieliauskas F, Shih YC. A review of economic impact of targeted oral anticancer medications. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):45-69.
Sodani K, Patel A, Anreddy N, Singh S, Yang DH, Kathawala RJ, Kumar P, Talele TT, Chen ZS. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochemical pharmacology. 2014 May;89(1):52-61.   PMCID: Pmc3983711
Sonpavde G, Bellmunt J, Rosenberg JE, Regazzi AM, Bajorin DF, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Pond GR. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Dec;12(6):395-8.
Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. Journal of hematology & oncology. 2014 Sep;7:58.   PMCID: 4172963
Tomaszewski JJ, Handorf E, Corcoran AT, Wong YN, Mehrazin R, Bekelman JE, Canter D, Kutikov A, Chen DY, Uzzo RG, Smaldone MC. Care transitions between hospitals are associated with treatment delay for patients with muscle invasive bladder cancer. J Urol. 2014 Nov;192(5):1349-54.   PMCID: PMC4422495
Vijayvergia N, Mehra R. Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2014 Sep;74(3):437-46.
von Mehren M, Britten CD, Pieslor P, Saville W, Vassos A, Harris S, Galluppi GR, Darif M, Wainberg ZA, Cohen RB, Leong S. A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun;32(3):518-25.   PMCID: Pmc4045341
Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS. The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget. 2014 Dec 30;5(24):12728-37.   PMCID: PMC4350349
Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 Feb 06;123(6):837-42.   PMCID: PMC5527396
Boland PM, Burtness B. Esophageal carcinoma: are modern targeted therapies shaking the rock?. Curr Opin Oncol. 2013 Jul;25(4):417-24.   PMCID: No NIH funding
Golovine KV, Makhov PB, Teper E, Kutikov A, Canter D, Uzzo RG, Kolenko VM. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. The Prostate. 2013 Jan;73(1):23-30.   PMCID: PMC3491117
Kotredes KP, Gamero AM. Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res. 2013 Apr;33(4):162-70.   PMCID: Pmc3624694
Movva S. Emerging therapies for sarcoma. Curr Probl Cancer. 2013 Mar;37(2):87-101.   PMCID: Review
Vadakara J, von Mehren M. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies. Hematol Oncol Clin North Am. 2013 Oct;27(5):905-20.   PMCID: Pmc3792495
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Antineoplastic Agents

Antineoplastic Agents drug therapy therapeutic use pharmacology Male methods pathology Neoplasms drug effects antagonists & inhibitors Female Aged metabolism genetics Middle Aged Monoclonal Antibodies Protein Kinase Inhibitors immunology Tumor Cell Line Molecular Targeted Therapy Mice Neoplasm Drug Resistance Adult Cell Proliferation adverse effects pharmacokinetics administration & dosage Neoplastic Gene Expression Regulation Maximum Tolerated Dose physiology Drug Dose-Response Relationship Oral Administration Urinary Bladder Neoplasms Drug Administration Schedule Pyridines therapy Follow-Up Studies Treatment Outcome RNA Interference Monoclonal Antibodies-Murine-Derived Rituximab Sarcoma Prognosis Diarrhea Receptor Protein-Tyrosine Kinases Genomics Inhibitor of Apoptosis Proteins cystectomy Lymphoma Telatinib Protein-Tyrosine Kinases Lung Neoplasms health care Mutation Proto-Oncogene Proteins c-abl Tablets Research Design Quality of Health Care Nuclear Proteins Pdgfra Cystectomy Protein Kinase C Reproducibility of Results Reactive Oxygen Species Bryostatins Drug Industry Gene Expression Profiling Soft Tissue Neoplasms Program Development blood 80 and over Aged Drug Delivery Systems Area Under Curve Kit Transitional Cell Carcinoma Molecular Models hospitals Pharmaceutical Solutions IGF Type 1 Receptor secretion Local Neoplasm Recurrence quality indicators mortality Non-Small-Cell Lung Carcinoma X-Ray Crystallography Oxidative Stress Salvage Therapy Magnetic Resonance Imaging Pancreatic Neoplasms Animal Disease Models Pyridazines Prostatic Neoplasms Nude Mice Hospitals Protein Transport Structure-Activity Relationship Gist Biological Availability adverse Igf-1r TOR Serine-Threonine Kinases Adenocarcinoma Cell Survival Cell Cycle Proteins Practice Guidelines as Topic Multiprotein Complexes effects Kidney Neoplasms Retrospective Studies ELAV Proteins ATP-Binding Cassette Transporters Gastrointestinal Stromal Tumors Smooth Muscle Multidrug resistance Cultured Tumor Cells Mass Spectrometry Bispecific Antibodies Thiazoles Insulin-Like Growth Factor II Hsp90 Androgen Receptors Interferons Antineoplastic Combined Chemotherapy Protocols Syndrome Molecular Structure supply & distribution Cytokines Dioxolanes Pyrazoles economics chemically induced Patient Care Neoplasm Antigens Neoplasm Proteins Central Nervous System Neoplasms Drug Costs Proteasome Endopeptidase Complex Immunotherapy Patient Selection Gastrointestinal Neoplasms Large B-Cell Lymphoma-Diffuse chemistry Neoplasm Invasiveness SDH-deficient GIST secondary Signal Transduction urinary bladder neoplasms Phase II Clinical Trials as Topic Neoplasm Staging Vomiting
Last updated on Friday, July 10, 2020